7 research outputs found
Timeline of key events in establishing and running the ELWA-III mobile EVD testing laboratory—September 2015 to March 2017.
<p>Timeline of key events in establishing and running the ELWA-III mobile EVD testing laboratory—September 2015 to March 2017.</p
RT-PCR Ct values for NP and GP gene targets from positive blood samples of EVD cases from the Duport Road cluster, November-December 2015 and the Central Monrovia cluster, March-April 2016.
<p>RT-PCR Ct values for NP and GP gene targets from positive blood samples of EVD cases from the Duport Road cluster, November-December 2015 and the Central Monrovia cluster, March-April 2016.</p
Representation of the layout of the ELWA-III mobile Ebola testing laboratory, at the ELWA Ebola treatment unit, Monrovia.
<p>Representation of the layout of the ELWA-III mobile Ebola testing laboratory, at the ELWA Ebola treatment unit, Monrovia.</p
Number of EVD specimens tested at ELWA III laboratory from initiation of testing in September 2015 to the end of 2016; displaying Duport Road and Central Monrovia clusters and the impact of the change to IDSR case definition on the numbers of specimens being processed at the laboratory.
<p>Number of EVD specimens tested at ELWA III laboratory from initiation of testing in September 2015 to the end of 2016; displaying Duport Road and Central Monrovia clusters and the impact of the change to IDSR case definition on the numbers of specimens being processed at the laboratory.</p
Case definition of suspect case of viral haemorrhagic fever as defined in the Integrated Disease Surveillance and Response (IDSR) Guidelines for Liberia.
<p>Case definition of suspect case of viral haemorrhagic fever as defined in the Integrated Disease Surveillance and Response (IDSR) Guidelines for Liberia.</p
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial
Background The effectiveness of the COVID-19 vaccination programme depends on mass participation: the greater
the number of people vaccinated, the less risk to the population. Concise, persuasive messaging is crucial, particularly
given substantial levels of vaccine hesitancy in the UK. Our aim was to test which types of written information about
COVID-19 vaccination, in addition to a statement of efficacy and safety, might increase vaccine acceptance.
Methods For this single-blind, parallel-group, randomised controlled trial, we aimed to recruit 15000 adults in the UK,
who were quota sampled to be representative. Participants were randomly assigned equally across ten information
conditions stratified by level of vaccine acceptance (willing, doubtful, or strongly hesitant). The control information
condition comprised the safety and effectiveness statement taken from the UK National Health Service website; the
remaining conditions addressed collective benefit, personal benefit, seriousness of the pandemic, and safety concerns.
After online provision of vaccination information, participants completed the Oxford COVID-19 Vaccine Hesitancy
Scale (outcome measure; score range 7–35) and the Oxford Vaccine Confidence and Complacency Scale (mediation
measure). The primary outcome was willingness to be vaccinated. Participants were analysed in the groups they were
allocated. p values were adjusted for multiple comparisons. The study was registered with ISRCTN, ISRCTN37254291.
Findings From Jan 19 to Feb 5, 2021, 15014 adults were recruited. Vaccine hesitancy had reduced from 26·9% the
previous year to 16·9%, so recruitment was extended to Feb 18 to recruit 3841 additional vaccine-hesitant adults.
12463 (66·1%) participants were classified as willing, 2932 (15·6%) as doubtful, and 3460 (18·4%) as strongly hesitant
(ie, report that they will avoid being vaccinated for as long as possible or will never get vaccinated). Information
conditions did not alter COVID-19 vaccine hesitancy in those willing or doubtful (adjusted p values >0·70). In those
strongly hesitant, COVID-19 vaccine hesitancy was reduced, in comparison to the control condition, by personal
benefit information (mean difference –1·49, 95% CI –2·16 to –0·82; adjusted p=0·0015), directly addressing safety
concerns about speed of development (–0·91, –1·58 to –0·23; adjusted p=0·0261), and a combination of all
information (–0·86, –1·53 to –0·18; adjusted p=0·0313). In those strongly hesitant, provision of personal benefit
information reduced hesitancy to a greater extent than provision of information on the collective benefit of not
personally getting ill (–0·97, 95% CI –1·64 to –0·30; adjusted p=0·0165) or the collective benefit of not transmitting
the virus (–1·01, –1·68 to –0·35; adjusted p=0·0150). Ethnicity and gender were found to moderate information
condition outcomes.
Interpretation In the approximately 10% of the population who are strongly hesitant about COVID-19 vaccines,
provision of information on personal benefit reduces hesitancy to a greater extent than information on collective
benefits. Where perception of risk from vaccines is most salient, decision making becomes centred on the personal.
As such, messaging that stresses the counterbalancing personal benefits is likely to prove most effective. The
messaging from this study could be used in public health communications. Going forwards, the study highlights
the need for future health campaigns to engage with the public on the terrain that is most salient to them
Residual Lung Abnormalities Following COVID-19 Hospitalization:Interim Analysis of the UKILD Post-COVID Study
RationaleShared symptoms and genetic architecture between COVID-19 and lung fibrosis suggests SARS-CoV-2 infection may lead to progressive lung damage.ObjectivesThe UKILD Post-COVID study interim analysis was planned to estimate the prevalence of residual lung abnormalities in people hospitalized with COVID-19 based on risk strata.MethodsThe Post-HOSPitalisation COVID Study (PHOSP-COVID) was used for capture of routine and research follow-up within 240 days from discharge. Thoracic CTs linked by PHOSP-COVID identifiers were scored for percentage of residual lung abnormalities (ground glass opacities and reticulations). Risk factors in linked CT were estimated with Bayesian binomial regression and risk strata were generated. Numbers within strata were used to estimate post-hospitalization prevalence using Bayesian binomial distributions. Sensitivity analysis was restricted to participants with protocol driven research follow-up.Measurements and main resultsThe interim cohort comprised 3700 people. Of 209 subjects with linked CTs (median 119 days, interquartile range 83-155), 166 people (79.4%) had >10% involvement of residual lung abnormalities. Risk factors included abnormal chest X-ray (RR 1·21 95%CrI 1·05; 1·40), percent predicted DLcoConclusionsResidual lung abnormalities were estimated in up to 11% of people discharged following COVID-19 related hospitalization. Health services should monitor at-risk individuals to elucidate long-term functional implications. This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/)